

19 December 2014

## TENDER RESULTS

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012 and the 2013/14 Invitation to Tender, dated 07 November 2013.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

### Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12<sup>th</sup> of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12<sup>th</sup> of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

**2012/13 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2016**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Escitalopram <sup>1.</sup>	tab 10 mg; 28 tablet, blister pack	\$2.65	\$1.40	Air Flow Products (Air Flow Products)	1 May 2015	1 July 2015	1 October 2015	Loxalate (Mylan)
Escitalopram <sup>1.</sup>	tab 20 mg; 28 tablet, blister pack	\$4.20	\$2.40	Air Flow Products (Air Flow Products)	1 May 2015	1 July 2015	1 October 2015	Loxalate (Mylan)
1. A Brand Switch Fee of \$4.33 is payable from 1 October 2015 until 1 January 2016								

**Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule**

2. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Escitalopram	tab 10 mg; 28 tablet, blister pack	\$2.65	\$1.40	Air Flow Products (Air Flow Products)	1%	1 May 2015	1 July 2015	Loxalate (Mylan)
Escitalopram	tab 20 mg; 28 tablet, blister pack	\$4.20	\$2.40	Air Flow Products (Air Flow Products)	1%	1 May 2015	1 July 2015	Loxalate (Mylan)

**2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

3. Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Triamcinolone acetonide	paste 0.1%; 5 g OP, tube	\$4.34	\$5.33	Kenalog in Orabase (Aspen)	1 February 2015	1 July 2015	Oracort (AFT)

4. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of subsidy change	Sole Subsidised Supply date
Emulsifying ointment	oint BP; 500 g, tub	\$3.04	\$2.73	AFT (AFT)	1 May 2015	1 August 2015
Triamcinolone acetonide	crm 0.02%; 100 g OP, tube	\$6.63	\$6.30	Aristocort (Aspen)	1 February 2015	1 May 2015
Triamcinolone acetonide	oint 0.02%; 100 g OP, tube	\$6.69	\$6.35	Aristocort (Aspen)	1 February 2015	1 May 2015
Triamcinolone acetonide	inj 10 mg per ml, 1 ml ampoule; 5 ampoules	\$21.90	\$20.80	Kenacort-A 10 (Aspen)	1 February 2015	1 May 2015
Triamcinolone acetonide	inj 40 mg per ml, 1 ml ampoule; 5 ampoules	\$53.79	\$51.10	Kenacort-A 40 (Aspen)	1 February 2015	1 May 2015

## Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

5. Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Triamcinolone acetonide	paste 0.1%; 5 g OP, tube	\$4.34	\$5.33	Kenalog in Orabase (Aspen)	1%	1 February 2015	1 April 2015	Oracort (AFT)

6. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Emulsifying ointment	oint BP; 500 g, tub	\$3.04	\$2.73	AFT (AFT)	1% <sup>1</sup>	1 May 2015	1 July 2015
Emulsifying ointment	oint BP; 100 g, tube	\$1.95	\$1.84	Jaychem (Jaychem)	1% <sup>2</sup>	1 February 2015	1 April 2015
Triamcinolone acetoneide	crm 0.02%; 100 g OP, tube	\$6.63	\$6.30	Aristocort (Aspen)	1%	1 February 2015	1 April 2015
Triamcinolone acetoneide	oint 0.02%; 100 g OP, tube	\$6.69	\$6.35	Aristocort (Aspen)	1%	1 February 2015	1 April 2015
Triamcinolone acetoneide	inj 10 mg per ml, 1 ml ampoule; 5 ampoules	\$21.90	\$20.80	Kenacort-A 10 (Aspen)	1%	1 February 2015	1 April 2015
Triamcinolone acetoneide	inj 40 mg per ml, 1 ml ampoule; 5 ampoules	\$53.79	\$51.10	Kenacort-A 40 (Aspen)	1%	1 February 2015	1 April 2015

1. Note: 1% DV limit applies to pack sizes of greater than 200 g.

2. Note: 1% DV limit applies to pack sizes of less than 200 g.

7. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Pack price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Paracetamol	tab soluble 500 mg; 20 tablet, foil pack	\$1.60	Paragesic Soluble (Rex Medical)	1%	1 August 2015	1 October 2015
Zinc and castor oil	oint, BP; 20 g, tube	\$1.39	healthE (Jaychem)	1%	1 March 2015	1 May 2015

For products included in the 2013/14 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.